(R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS

• US 20120041026A1
• Filed: 02/16/2011
• Published: 02/16/2012
• Est. Priority Date: 02/16/2010
• Status: Abandoned Application

• Current Assignee: Pfizer Inc.
• Original Assignee: Pfizer Inc.
• Inventors: Noguchi, Hirohide, Waizumi, Nobuaki
• Application Number:
  US13/028,368
• Publication Number:
  US 20120041026A1
• Time in Patent Office: Days
• US Class Current: 514/321
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07D 413/14 containing three or more hetero rings

Abstract

(R)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol and its use in treating neurodegenerative disorders, is described herein.

Claims

1. (R)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol, or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

4. A method of treating a neurodegenerative disease or disorder, the method comprising administering a therapeutically effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof.

5. The method according to claim 4, wherein the neurodegenerative disease or disorder is dementia, Alzheimer'"'"'s disease, depression, psychosis, schizophrenia, anxiety, mood disorders, attention deficit/hyperactivity disorder, or attention deficit disorder.

6. The method according to claim 5, wherein the neurodegenerative disease or disorder is Alzheimer'"'"'s disease.

7. The method according to claim 5, wherein the neurodegenerative disease is dementia.

8. The method of claim 4, wherein the therapeutically effective amount ranges from about 0.01 mg/kg to about 100 mg/kg.

2. A compound of formula X: